



Dushyanth Surakanti, CEO



ds@spartabio.com



317.340.3304



www.bioenthesi.com

Approximately 30,000,000 people in the United States are living with a torn rotator cuff. However, the success rates for surgical repair is wildly variable, ranging anywhere from 30-90%. This high rate of rotator cuff retears, and the resulting need for revision surgery, decreases patient satisfaction and increases costs that are passed on to patients, hospitals, and insurance carriers - creating an environment wherein multiple parties are incentivized to find ways to reduce the rate of rotator cuff re-tear and failure.

SCIENTIFIC ADVISORY BOARD



**ADAM
YANKE**
MD, PhD



**BRIAN
WATERMAN**
MD



**MIKE
FREHILL**
MD



**JAMES
GREGORY**
MD



**GEOFF
ABRAMS**
MD



**GRANT
GARRIGUES**
MD



**JEFF
GIULIANI**
MD



**JON
DICKENS**
MD, COL

LEADERSHIP TEAM



Dushyanth Surakanti
FOUNDER, CEO



Dimitrios Angelis
FOUNDER, PRESIDENT



Demetrius Siachames
VP, ENGINEERING



Travis Entrop
SR. ENGINEER



Adam Martinez, PhD
R&D CONSULTANT

Why do rotator cuff repairs fail



TEAR ANATOMY



PATIENT HEALTH



SURGICAL APPROACH

Solution



**First of its Kind
Biphasic Allograft**

Features & Benefit


- Directly addresses the enthesis, where healing occurs
- Ensures full contact between bone/graft/tendon
- Absorbs and retains biofluids
- Customizable size/shape
- No immunogenic response

Healing [of the rotator cuff] relies on reincorporation of the tendon into the bone at the enthesis

Clinical Evidence

	BIOENTHESIS	CONTROL	P VALUE
n	10	20	-
Age (yrs)	67.4 +/- 6.6	55.1 +/- 9.7	<0.001
MRI - Sugaya Score (12m)	2.3 +/- 0.7	3.3 +/- 1.0	0.013
Retear Rate 12m)	10%	50%	0.048

EXEMPLARY MRIS



Patents

OWNED

3 Issued US Utility Patents
1 Allowed US Process Patent
4 US Patent Applications

LICENSED

4 Issued US Utility Patents
2 Issued EX-US Patents
(China, Canada, EU)

TRADEMARKS

1 US Registered Trademark

”

BioEnthesis® is a clinically sound option for surgeons looking to help their patients. It is imperative for us to have all available tools to improve long term healing. Biologics are the future of tendon-to-bone healing, and this is the bridge to that future.

• **James Gregory, MD**
UNIVERSITY OF TEXAS HEALTH

”

The clinical study shows that BioEnthesis® should be strongly considered when treating patients with full thickness tears.

• **Adam Yanke, MD, PhD**
MIDWEST ORTHOPEDICS AT RUSH